CEO Michael Narachi, "This agreement expands and diversifies our existing commercial supply network and will help ensure we will be ready to supply Contrave globally if approved.
Assuming successful completion of the review process and potential approval in the second half of 2014, Orexigen
would expect Contrave to be available to physicians and their patients in Europe in early 2015.
In exchange for undisclosed upfront and future milestone payments, Orexigen
secured non-exclusive rights to certain formulation patents related to bupropion, one of the constituents of Contrave.
An interim analysis and New Drug Application resubmission are planned once approximately 87 MACE events have occurred, which Orexigen
anticipates will occur in the second half of 2013.
scientists leverage this understanding to develop novel combination drug regimens designed to initiate and then sustain weight loss by mitigating compensatory mechanisms that result in an early weight loss plateau.
The webcast can be accessed live on the investor relations section of the Orexigen
web site at www.
In November, Orexigen
announced that enrollment was complete in the first of its four Phase III clinical trials, NB-302.
SAN DIEGO, June 18, 2015 /PRNewswire/ -- Orexigen
Baum brings to Orexigen
over twelve years of experience in pharmaceutical product marketing and strategic planning.
para]]SAN DIEGO, June 5, 2015 /PRNewswire/ -- Orexigen
This patent, upon issuance, both strengthens and broadens the scope of our intellectual property position for this novel, proprietary drug combination," said Orexigen
President and CEO, Gary Tollefson, M.
SAN DIEGO, May 8, 2015 /PRNewswire/ -- Orexigen